|
Schizophrenia
|
0.440 |
GeneticVariation
|
disease |
BEFREE |
Previous genome-wide association studies (GWAS) suggest that rs10489202 in the intron of MPC2 (mitochondrial pyruvate carrier 2) is a risk locus for schizophrenia in Han Chinese populations.
|
30087317 |
2018 |
|
Schizophrenia
|
0.440 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to test the association between the NKAPL rs1635, TSPAN18 rs11038167, and MPC2 rs10489202 polymorphisms and SZ in a Chinese population.
|
27460766 |
2017 |
|
Schizophrenia
|
0.440 |
GeneticVariation
|
disease |
BEFREE |
The results showed that rs10489202 in MPC2 (BRP44) is significantly associated with schizophrenia in these East Asian replication samples (one-tailed P=5.75×10(-3), OR=1.12), and further meta-analysis after including previous GWAS data yielded a genome-wide significant association (two-tailed P=1.11×10(-10), OR=1.19), adding further support for the involvement of this locus in the genetic risk of schizophrenia, and future studies regarding the underlying molecular mechanisms of the risk association are necessary.
|
26899211 |
2016 |
|
Schizophrenia
|
0.440 |
GeneticVariation
|
disease |
BEFREE |
A recent genome-wide association study (GWAS) of Han Chinese identified a single-nucleotide polymorphism (SNP, rs10489202) in the mitochondrial pyruvate carrier 2 gene (MPC2, also known as BRP44) as a possible susceptibility locus for schizophrenia.
|
23933155 |
2013 |
|
Schizophrenia
|
0.440 |
GeneticVariation
|
disease |
GWASDB |
Common variants on 8p12 and 1q24.2 confer risk of schizophrenia.
|
22037555 |
2011 |
|
Schizophrenia
|
0.440 |
GeneticVariation
|
disease |
GWASCAT |
Common variants on 8p12 and 1q24.2 confer risk of schizophrenia.
|
22037555 |
2011 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.
|
27903959 |
2017 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
MPC1 mRNA levels were decreased in each cancer sample, while a mixture of increased and decreased MPC2 mRNA levels observed in the HCC samples.
|
29805642 |
2018 |
|
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
MPC1 mRNA levels were decreased in each cancer sample, while a mixture of increased and decreased MPC2 mRNA levels observed in the HCC samples.
|
29805642 |
2018 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Positive MPC1 or MPC2 expression in cancer tissues was significantly associated with higher OS (P < 0.05).
|
27852261 |
2016 |
|
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Positive MPC1 or MPC2 expression in cancer tissues was significantly associated with higher OS (P < 0.05).
|
27852261 |
2016 |
|
Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Consistently, neither MPC1 nor MPC2 was predictive in a glioblastoma data set containing 5% IDH-mutant cases.
|
29547090 |
2018 |
|
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A clinical risk score using IDH and 1p19q status, age, KPS score, and MPC1 and MPC2 z-scores defined 4 risk categories for lower-grade glioma; this score was validated using a secondary glioma data set.
|
29547090 |
2018 |
|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Consequently, restoring MPC1 and MPC2 in human tumor cells decreases free NADH and inhibits melanoma cell proliferation and migration.
|
30356033 |
2018 |
|
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Within the IDH-stratified lower-grade glioma data set, MPC1 status distinguished improved survival in 1p19q-codeleted tumors (p < 0.05), whereas MPC2 expression delineated worsened survival in 1p19q-intact tumors (p < 0.01).
|
29547090 |
2018 |
|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Consistently, neither MPC1 nor MPC2 was predictive in a glioblastoma data set containing 5% IDH-mutant cases.
|
29547090 |
2018 |
|
Childhood Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Consistently, neither MPC1 nor MPC2 was predictive in a glioblastoma data set containing 5% IDH-mutant cases.
|
29547090 |
2018 |
|
Glioblastoma Multiforme
|
0.010 |
Biomarker
|
disease |
BEFREE |
Consistently, neither MPC1 nor MPC2 was predictive in a glioblastoma data set containing 5% IDH-mutant cases.
|
29547090 |
2018 |
|
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MPC1 mRNA levels were decreased in each cancer sample, while a mixture of increased and decreased MPC2 mRNA levels observed in the HCC samples.
|
29805642 |
2018 |
|
Familial lichen amyloidosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, the expression status of MPC1 and MPC2 in prostate cancer (PCA) is unclear.
|
27852261 |
2016 |
|
Malignant neoplasm of prostate
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, expression of MPC1 and MPC2 in LNCaP and DU145 prostate cancer cell lines was examined by immunocytochemistry (ICC) and Western blotting.
|
27852261 |
2016 |
|
Prostate carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, expression of MPC1 and MPC2 in LNCaP and DU145 prostate cancer cell lines was examined by immunocytochemistry (ICC) and Western blotting.
|
27852261 |
2016 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
While UICC stage (P < 0.001) and lymph node metastasis (P = 0.002) were negatively associated with MPC2 expression.
|
27852261 |
2016 |